Laila F. Jerman

Laila F. Jerman

Auto-generated profile, based on publicly available information

Laila F. Jerman

Department of Human Genetics, Sidra Medicine, Doha P.O. Box 26999, Qatar

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
AAAmmira Akil
Ammira Akil
LJLaila F. Jerman
Laila F. Jerman
EYEsraa Yassin
Esraa Yassin
SPSujitha S. Padmajeya
Sujitha S. Padmajeya
AAAlya Al-Kurbi
Alya Al-Kurbi
KFKhalid A. Fakhro
Khalid A. Fakhro
Type 1 diabetes (T1D) is an autoimmune condition where the body’s immune cells destroy their insulin-producing pancreatic beta cells leading to dysregulated glycaemia. Individuals with T1D control their blood glucose through exogenous insulin replacement therapy, often using multiple daily injections or pumps. However, failure to accurately mimic intrinsic glucose regulation results in glucose fluctuations and long-term complications impacting key organs such as the heart, kidneys, and/or the eyes. It is well established that genetic and environmental factors contribute to the initiation and progression of T1D, but recent studies show that epigenetic modifications are also important. Here, we discuss key epigenetic modifications associated with T1D pathogenesis and discuss how recent research is finding ways to harness epigenetic mechanisms to prevent, reverse, or manage T1D.